David A. Siegel Biotechnology

Two Sigma Advisers, LP

$46.1 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
REGN Regeneron Pharmaceuticals, Inc.	$59.7B	$493 Million 1.07% of portfolio	938,500	Q2 2025 Added 69.47%
MRNA Moderna, Inc.	$10B	$216 Million 0.47% of portfolio	7,815,700	Q2 2025 Added 105.22%
IONS Ionis Pharmaceuticals Inc	$5.85B	$105 Million 0.23% of portfolio	2,667,611	Q2 2025 Added 27.51%
NVO Novo Nordisk A S	$112B	$96.1 Million 0.21% of portfolio	1,391,700	Q2 2025 Reduced 71.35%
ALNY Alnylam Pharmaceuticals, Inc.	$52.9B	$86.8 Million 0.19% of portfolio	266,100	Q2 2025 Reduced 3.52%
BBIO Bridge Bio Pharma, Inc.	$7.28B	$72.7 Million 0.16% of portfolio	1,684,055	Q2 2025 Added 516.52%
CRSP Crispr Therapeutics Ag	$4.42B	$65.4 Million 0.14% of portfolio	1,344,700	Q2 2025 Added 68.68%
BCRX Biocryst Pharmaceuticals Inc	$1.55B	$37.9 Million 0.08% of portfolio	4,228,412	Q2 2025 Added 31.29%
GMAB Genmab A/S	$14.4B	$37.6 Million 0.08% of portfolio	1,821,000	Q2 2025 Reduced 7.74%
SRPT Sarepta Therapeutics, Inc.	$1.6B	$34 Million 0.07% of portfolio	1,985,734	Q2 2025 Added 618.6%
RARE Ultragenyx Pharmaceutical Inc.	$1.97B	$31.3 Million 0.07% of portfolio	860,400	Q2 2025 Reduced 8.19%
RPRX Royalty Pharma PLC	$15.7B	$30.5 Million 0.07% of portfolio	846,900	Q2 2025 Reduced 70.84%
VKTX Viking Therapeutics, Inc.	$3.06B	$28.9 Million 0.06% of portfolio	1,091,428	Q2 2025 New
LEGN Legend Biotech Corp	$6.19B	$25.4 Million 0.06% of portfolio	716,100	Q2 2025 Added 42.06%
NTLA Intellia Therapeutics, Inc.	$825M	$19.6 Million 0.04% of portfolio	2,093,017	Q2 2025 Added 5.58%
EXEL Exelixis, Inc.	$12.1B	$18.9 Million 0.04% of portfolio	428,790	Q2 2025 Reduced 81.24%
ADMA Adma Biologics, Inc.	$3.29B	$18.8 Million 0.04% of portfolio	1,033,400	Q2 2025 Reduced 60.05%
IMCR Immunocore Holdings PLC	$1.4B	$16.1 Million 0.03% of portfolio	512,430	Q2 2025 Reduced 2.1%
TVTX Travere Therapeutics, Inc.	$1.12B	$15.7 Million 0.03% of portfolio	1,057,700	Q2 2025 Added 1.15%
HALO Halozyme Therapeutics, Inc.	$8.95B	$14.8 Million 0.03% of portfolio	285,400	Q2 2025 Reduced 2.84%
ABCL Ab Cellera Biologics Inc.	$1.22B	$14 Million 0.03% of portfolio	4,070,300	Q2 2025 Added 53.9%
MNKD Mannkind Corp	$942M	$12.7 Million 0.03% of portfolio	3,386,727	Q2 2025 Reduced 9.34%
MRUS Merus N.V.	$2.93B	$10.2 Million 0.02% of portfolio	194,800	Q2 2025 Reduced 64.86%
KYMR Kymera Therapeutics, Inc.	$2.18B	$9.79 Million 0.02% of portfolio	224,300	Q2 2025 Added 22.37%
CORT Corcept Therapeutics Inc	$7.88B	$9.55 Million 0.02% of portfolio	130,100	Q2 2025 Reduced 57.59%
BEAM Beam Therapeutics Inc.	$1.19B	$9.41 Million 0.02% of portfolio	553,100	Q2 2025 Added 427.26%
QURE Uni Qure N.V.	$668M	$9.2 Million 0.02% of portfolio	659,700	Q2 2025 Reduced 1.32%
MIRM Mirum Pharmaceuticals, Inc.	$2.38B	$8.72 Million 0.02% of portfolio	171,400	Q2 2025 Reduced 17.04%
ARGX Argenx Se	$35.3B	$7.72 Million 0.02% of portfolio	14,000	Q2 2025 Reduced 53.64%
AVXL Anavex Life Sciences Corp.	$840M	$7.59 Million 0.02% of portfolio	823,400	Q2 2025 Added 62.02%
INVA Innoviva, Inc.	$1.4B	$6.38 Million 0.01% of portfolio	317,800	Q2 2025 Reduced 44.39%
ARWR Arrowhead Pharmaceuticals, Inc.	$1.88B	$6.19 Million 0.01% of portfolio	391,800	Q2 2025 Reduced 45.87%
IDYA Ideaya Biosciences, Inc.	$1.13B	$5.6 Million 0.01% of portfolio	266,600	Q2 2025 Reduced 35.54%
MRVI Maravai Lifesciences Holdings, Inc.	$354M	$5.36 Million 0.01% of portfolio	2,224,594	Q2 2025 Reduced 0.6%
FOLD Amicus Therapeutics, Inc.	$1.96B	$5.14 Million 0.01% of portfolio	896,576	Q2 2025 Reduced 13.23%
XERS Xeris Biopharma Holdings, Inc.	$992M	$4.94 Million 0.01% of portfolio	1,056,779	Q2 2025 Added 14.17%
ARDX Ardelyx, Inc.	$866M	$4.85 Million 0.01% of portfolio	1,236,500	Q2 2025 Added 108.13%
XNCR Xencor Inc	$463M	$4.55 Million 0.01% of portfolio	579,300	Q2 2025 Added 45.44%
APLS Apellis Pharmaceuticals, Inc.	$2.63B	$4.45 Million 0.01% of portfolio	256,800	Q2 2025 Added 33.89%
TGTX Tg Therapeutics, Inc.	$3.94B	$4.44 Million 0.01% of portfolio	123,500	Q2 2025 Reduced 6.72%
VERV Verve Therapeutics, Inc.	$667M	$4.28 Million 0.01% of portfolio	381,300	Q2 2025 Added 119.39%
ACAD Acadia Pharmaceuticals Inc	$4.12B	$4.2 Million 0.01% of portfolio	194,900	Q2 2025 Reduced 79.86%
LQDA Liquidia Corp	$1.55B	$4.04 Million 0.01% of portfolio	324,400	Q2 2025 Added 12.72%
IOVA Iovance Biotherapeutics, Inc.	$352M	$4.02 Million 0.01% of portfolio	2,334,900	Q2 2025 New
RLAY Relay Therapeutics, Inc.	$403M	$3.94 Million 0.01% of portfolio	1,139,800	Q2 2025 Added 51.73%
VNDA Vanda Pharmaceuticals Inc.	$244M	$3.82 Million 0.01% of portfolio	809,200	Q2 2025 Added 244.05%
SNDX Syndax Pharmaceuticals Inc	$734M	$3.68 Million 0.01% of portfolio	392,452	Q2 2025 Reduced 22.0%
RCKT Rocket Pharmaceuticals, Inc.	$220M	$3.65 Million 0.01% of portfolio	1,490,251	Q2 2025 New
LRMR Larimar Therapeutics, Inc.	$160M	$3.31 Million 0.01% of portfolio	1,146,924	Q2 2025 Added 191.08%
NRIX Nurix Therapeutics, Inc.	$472M	$3.24 Million 0.01% of portfolio	284,600	Q2 2025 Added 45.65%

Shares Options

David A. Siegel

David A. Siegel is the co-founder and CEO of Two Sigma Advisers, a successful investment firm that uses technology and data-driven approaches to investing. Siegel is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track David A. Siegel's portfolio

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account